US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance
Countering Strategies In Play
While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.
You may also be interested in...
Amid US Cough Syrup Findings, Regulators Feel India Needs To Work On Perceptions But Also Make Improvements
In wake of the furore caused by OTC cough syrups made by two small Indian companies, former and current US FDA and MHRA officials say quality-related issues are not specific to India. However, while image management needs some work, manufacturers in the country also need to make further improvements to ensure quality.
BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic
Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics
Torrent’s Brazil Growth Surges 36% In Q3
Torrent’s quarterly revenues were up by 18% to INR24.9bn in Q3 FY2023. Branded generics and the Brazilian market did much of the heavy lifting.